New investors join Draper Associates and Boost VC as the company moves its lead cell therapy toward human trials and develops its second-generation injectable
SAN FRANCISCO, CA, UNITED STATES, September 15, 2026 /EINPresswire.com/ — HexemBio, the rapidly advancing longevity company, today announced a three-generation product line built on its synthetic biology platform, supported by $15.5 million in total funding. Three new investors have joined the company’s backers including Happiness Capital, alongside additional capital from lead investor Draper Associates and Boost VC.
HexemBio’s first generation lead program is a cell therapy that rejuvenates a patient’s own blood stem cells rather than replacing or reprogramming them. The company’s Synthetic Human Yolk Sac recreates the developmental environment where the body’s first blood stem cells arise. A patient’s aged cells are briefly returned to that environment outside the body, then infused back. The platform was published in Nature, with additional manuscripts under review. HexemBio has filed 17 patent applications worldwide, two of which have been granted.
The first generation cell therapy program targets bone marrow transplant improvement in patients with blood disease. HexemBio received Orphan Drug Designation for the program in July 2025, completed its Pre-IND meeting in January 2026, and is targeting first-in-human trials in 2027.
The second generation is an injectable that carries defined signals from the same developmental environment without requiring cells to be collected. It is being developed for patients who would benefit from restored stem cell function outside the transplant setting. The program is currently in advanced preclinical development.
A third generation product to enhance and protect skin is currently in its final phase of development with an aggressive go-to-market strategy.
“Our first generation product and lead program for transplants is still the main priority to get into human clinical trials for 2027,” said Gabriel Levesque Tremblay, CEO and Co-Founder of HexemBio. “Our goal is to create accessible therapies that extend healthy years.”
“Our mission is to co-create a happier and healthier world for all,” said Eric Ng, CEO. “We are excited by HexemBio’s approach to targeting the foundational drivers of aging, which will help people extend their healthspan and deliver benefits that resonate across generations.”
Draper Associates backs early-stage science, with recent investments in companies working on artificial wombs and de-extinction alongside earlier bets on Tesla, SpaceX, Coinbase, Robinhood, and Colossal.
“We invested in HexemBio’s first therapy, and we are thrilled with their progress. The team has been outstanding. Their fundamental breakthrough technology has expanded into three new product categories, maybe more to come.” said Tim Draper, Founding Partner at Draper Associates.”
###
About HexemBio
HexemBio is a longevity and AI discovery company that develops regenerative therapies for aging blood stem cells. Its Synthetic Human Yolk Sac technology recreates the developmental environment where blood stem cells first arise. Using machine learning, HexemBio was able to identify a defined molecular recipe that rejuvenates aged hematopoietic stem cells. By restoring the regenerative capacity of a patient’s own cells, HexemBio aims to improve outcomes in bone marrow transplantation and extend human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from Berkeley and New York City.
To learn more, visit hexemb.io.
Kamila Khasanova
On Top Strategy
kamila@ontopstrategy.com
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
